BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Draghiciu O, Nijman HW, Hoogeboom BN, Meijerhof T, Daemen T. Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology 2015;4:e989764. [PMID: 25949902 DOI: 10.4161/2162402X.2014.989764] [Cited by in Crossref: 67] [Cited by in F6Publishing: 40] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Gargett T, Christo SN, Hercus TR, Abbas N, Singhal N, Lopez AF, Brown MP. GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro. Clin Transl Immunology 2016;5:e119. [PMID: 28090321 DOI: 10.1038/cti.2016.80] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
2 du Plessis N, Kotze LA, Leukes V, Walzl G. Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis. Front Cell Infect Microbiol 2018;8:332. [PMID: 30298121 DOI: 10.3389/fcimb.2018.00332] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
3 Bryant AJ, Shenoy V, Fu C, Marek G, Lorentsen KJ, Herzog EL, Brantly ML, Avram D, Scott EW. Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension. Am J Respir Cell Mol Biol 2018;58:170-80. [PMID: 28862882 DOI: 10.1165/rcmb.2017-0214OC] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
4 Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology 2017;6:e1331807. [PMID: 28811975 DOI: 10.1080/2162402X.2017.1331807] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 10.4] [Reference Citation Analysis]
5 McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018;24:749-57. [PMID: 29867230 DOI: 10.1038/s41591-018-0053-3] [Cited by in Crossref: 438] [Cited by in F6Publishing: 407] [Article Influence: 109.5] [Reference Citation Analysis]
6 Liu D, Li G, Avella DM, Kimchi ET, Kaifi JT, Rubinstein MP, Camp ER, Rockey DC, Schell TD, Staveley-O'Carroll KF. Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer. Oncoimmunology 2017;7:e1372079. [PMID: 29296523 DOI: 10.1080/2162402X.2017.1372079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
7 Karlsson-Parra A, Kovacka J, Heimann E, Jorvid M, Zeilemaker S, Longhurst S, Suenaert P. Ilixadencel - an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. Pharm Res 2018;35:156. [PMID: 29904904 DOI: 10.1007/s11095-018-2438-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Huo M, Zhao Y, Satterlee AB, Wang Y, Xu Y, Huang L. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release 2017;245:81-94. [PMID: 27863995 DOI: 10.1016/j.jconrel.2016.11.013] [Cited by in Crossref: 75] [Cited by in F6Publishing: 83] [Article Influence: 12.5] [Reference Citation Analysis]
9 Haas L, Obenauf AC. Allies or Enemies-The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment. Front Immunol 2019;10:2746. [PMID: 31849950 DOI: 10.3389/fimmu.2019.02746] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
10 Loskog A. Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles. Viruses 2015;7:5780-91. [PMID: 26561829 DOI: 10.3390/v7112899] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
11 Lecot P, Sarabi M, Pereira Abrantes M, Mussard J, Koenderman L, Caux C, Bendriss-Vermare N, Michallet MC. Neutrophil Heterogeneity in Cancer: From Biology to Therapies. Front Immunol 2019;10:2155. [PMID: 31616408 DOI: 10.3389/fimmu.2019.02155] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 18.3] [Reference Citation Analysis]
12 Li JY, Chen YP, Li YQ, Liu N, Ma J. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer 2021;20:27. [PMID: 33541368 DOI: 10.1186/s12943-021-01317-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
13 Becker T, Elbahesh H, Reperant LA, Rimmelzwaan GF, Osterhaus ADME. Influenza Vaccines: Successes and Continuing Challenges. J Infect Dis 2021;224:S405-19. [PMID: 34590139 DOI: 10.1093/infdis/jiab269] [Reference Citation Analysis]
14 Fecek RJ, Storkus WJ. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy 2016;8:1205-18. [PMID: 27605069 DOI: 10.2217/imt-2016-0071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
15 Mandula JK, Rodriguez PC. Tumor-related stress regulates functional plasticity of MDSCs. Cell Immunol 2021;363:104312. [PMID: 33652258 DOI: 10.1016/j.cellimm.2021.104312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. Cancer Immunol Immunother 2019;68:1025-35. [PMID: 30852622 DOI: 10.1007/s00262-019-02320-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Zhu H, Liu Q, Miao L, Musetti S, Huo M, Huang L. Remodeling the fibrotic tumor microenvironment of desmoplastic melanoma to facilitate vaccine immunotherapy. Nanoscale 2020;12:3400-10. [PMID: 31989142 DOI: 10.1039/c9nr09610h] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
18 Sun B, Hyun H, Li LT, Wang AZ. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment. Acta Pharmacol Sin 2020;41:970-85. [PMID: 32424240 DOI: 10.1038/s41401-020-0424-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
19 Kishimoto T, Fujimoto N, Ebara T, Omori T, Oguri T, Niimi A, Yokoyama T, Kato M, Usami I, Nishio M, Yoshikawa K, Tokuyama T, Tamura M, Yokoyama Y, Tsuboi K, Matsuo Y, Xu J, Takahashi S, Abdelgied M, Alexander WT, Alexander DB, Tsuda H. Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients. BMC Cancer 2019;19:1204. [PMID: 31823764 DOI: 10.1186/s12885-019-6419-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
20 Noé G, Bellesoeur A, Thomas-Schoemann A, Rangarajan S, Naji F, Puszkiel A, Huillard O, Saidu N, Golmard L, Alexandre J, Goldwasser F, Blanchet B, Vidal M. Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib. Oncotarget 2016;7:67507-20. [PMID: 27589830 DOI: 10.18632/oncotarget.11686] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
21 Tannir NM, Pal SK, Atkins MB. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. Oncologist. 2018;23:540-555. [PMID: 29487224 DOI: 10.1634/theoncologist.2017-0534] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
22 Lim J, Lee A, Lee HG, Lim JS. Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells. Biomol Ther (Seoul) 2020;28:1-17. [PMID: 31431006 DOI: 10.4062/biomolther.2019.069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Peng C, Rabold K, Mulder WJM, Jaeger M, Netea-Maier RT. Kinase Inhibitors' Effects on Innate Immunity in Solid Cancers. Cancers (Basel) 2021;13:5695. [PMID: 34830850 DOI: 10.3390/cancers13225695] [Reference Citation Analysis]
24 Bandara NA, Bates CD, Lu Y, Hoylman EK, Low PS. Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer. Mol Cancer Ther 2017;16:461-8. [PMID: 27980109 DOI: 10.1158/1535-7163.MCT-16-0569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
25 Zheng J, Gao P. Toward Normalization of the Tumor Microenvironment for Cancer Therapy. Integr Cancer Ther 2019;18:1534735419862352. [PMID: 31282197 DOI: 10.1177/1534735419862352] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
26 Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to Modulate Antitumor Immunity. Front Immunol 2018;9:978. [PMID: 29774034 DOI: 10.3389/fimmu.2018.00978] [Cited by in Crossref: 164] [Cited by in F6Publishing: 165] [Article Influence: 41.0] [Reference Citation Analysis]
27 Lu LC, Chang CJ, Hsu CH. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. J Hepatocell Carcinoma. 2019;6:71-84. [PMID: 31123667 DOI: 10.2147/jhc.s159693] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
28 Jayashankar L, Hafner R. Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination. Front Immunol 2016;7:577. [PMID: 28018344 DOI: 10.3389/fimmu.2016.00577] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
29 Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM. Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Sci Rep 2016;6:31397. [PMID: 27507680 DOI: 10.1038/srep31397] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
30 Tan HY, Wang N, Lam W, Guo W, Feng Y, Cheng YC. Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol Cancer 2018;17:43. [PMID: 29455663 DOI: 10.1186/s12943-018-0800-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 10.5] [Reference Citation Analysis]
31 Kim M, Nitschké M, Sennino B, Murer P, Schriver BJ, Bell A, Subramanian A, McDonald CE, Wang J, Cha H, Bourgeois-Daigneault MC, Kirn DH, Bell JC, De Silva N, Breitbach CJ, McDonald DM. Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. Cancer Res 2018;78:922-37. [PMID: 29259007 DOI: 10.1158/0008-5472.CAN-15-3308] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
32 Draghiciu O, Boerma A, Hoogeboom BN, Nijman HW, Daemen T. A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development. Oncoimmunology 2015;4:e1029699. [PMID: 26451295 DOI: 10.1080/2162402X.2015.1029699] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
33 Dufait I, Van Valckenborgh E, Menu E, Escors D, De Ridder M, Breckpot K. Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. Oncotarget 2016;7:42698-715. [PMID: 27029037 DOI: 10.18632/oncotarget.8311] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
34 Zöller M. Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease. Front Immunol 2018;9:137. [PMID: 29456536 DOI: 10.3389/fimmu.2018.00137] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
35 Li Z, Liu Y, Fang X, Shu Z. Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. Int J Nanomedicine 2021;16:1631-61. [PMID: 33688183 DOI: 10.2147/IJN.S290346] [Reference Citation Analysis]
36 Fu SY, Wang CC, Chen FH, Yu CF, Hong JH, Chiang CS. Sunitinib Treatment-elicited Distinct Tumor Microenvironment Dramatically Compensated the Reduction of Myeloid-derived Suppressor Cells. In Vivo 2020;34:1141-52. [PMID: 32354903 DOI: 10.21873/invivo.11886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther 2021;6:362. [PMID: 34620838 DOI: 10.1038/s41392-021-00670-9] [Reference Citation Analysis]
38 Ding AS, Routkevitch D, Jackson C, Lim M. Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors. Front Immunol 2019;10:1715. [PMID: 31396227 DOI: 10.3389/fimmu.2019.01715] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
39 Szebeni GJ, Vizler C, Nagy LI, Kitajka K, Puskas LG. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets. Int J Mol Sci 2016;17:E1958. [PMID: 27886105 DOI: 10.3390/ijms17111958] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
40 Hao Z, Sadek I. Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther 2016;9:5495-505. [PMID: 27660467 DOI: 10.2147/OTT.S112242] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
41 Yaseen MM, Abuharfeil NM, Darmani H. Myeloid-derived suppressor cells and the pathogenesis of human immunodeficiency virus infection. Open Biol 2021;11:210216. [PMID: 34753323 DOI: 10.1098/rsob.210216] [Reference Citation Analysis]
42 Frosch J, Leontari I, Anderson J. Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment. Cancers (Basel) 2021;13:1743. [PMID: 33917501 DOI: 10.3390/cancers13071743] [Reference Citation Analysis]